Pharsight

Actoplus Met Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8668931 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(6 months ago)

US8470368 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(6 months ago)

US9060941 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(6 months ago)

US7785627 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(2 years from now)

US7959946 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(2 years from now)

Actoplus Met Xr is owned by Takeda Pharms Usa.

Actoplus Met Xr contains Metformin Hydrochloride; Pioglitazone Hydrochloride.

Actoplus Met Xr has a total of 5 drug patents out of which 3 drug patents have expired.

Expired drug patents of Actoplus Met Xr are:

  • US8668931
  • US8470368
  • US9060941

Actoplus Met Xr was authorised for market use on 12 May, 2009.

Actoplus Met Xr is available in tablet, extended release;oral dosage forms.

The generics of Actoplus Met Xr are possible to be released after 31 July, 2026.

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 12 May, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ACTOPLUS MET XR before it's drug patent expiration?
More Information on Dosage

ACTOPLUS MET XR family patents

Family Patents